Evidence map›Paper›PMID 41828543›Full record

ArticleInternational journal of molecular sciences2026

Dose-Dependent Neuroprotective Effects of Valproate on Motor Function and Striatal D2 Receptor Stability in a 6-OHDA Rat Model of Parkinson's Disease.

Alfonso Alfaro-Rodríguez, Angélica González-Maciel, Samuel Reyes Long, Beatriz Pérez-Guille, Rosa Eugenia Soriano-Rosales, José Francisco Gonzalez-Zamora, Herlinda Bonilla-Jaime, José Luis Cortes-Altamirano

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Alfonso Alfaro-RodríguezDivisión de Neurociencias Básicas, Instituto Nacional de Rehabilitación-LGII, México City 14389, Mexico.ORCID 0000-0002-4599-1253
Angélica González-MacielLaboratorio de Morfología Celular y Tisular, Instituto Nacional de Pediatría, Secretaría de Salud, México City 04300, Mexico.
Samuel Reyes LongDivisión de Neurociencias Básicas, Instituto Nacional de Rehabilitación-LGII, México City 14389, Mexico.ORCID 0000-0002-8916-0814
Beatriz Pérez-GuilleTranslational Research Center, Instituto Nacional de Pediatría, Mexico City 04300, Mexico.
Rosa Eugenia Soriano-RosalesTranslational Research Center, Instituto Nacional de Pediatría, Mexico City 04300, Mexico.
José Francisco Gonzalez-ZamoraTranslational Research Center, Instituto Nacional de Pediatría, Mexico City 04300, Mexico.ORCID 0000-0001-5444-270X
Herlinda Bonilla-JaimeDepartamento de Biología de la Reproducción, Universidad Autónoma Metropolitana, Ciudad de México 09340, Mexico.
José Luis Cortes-AltamiranoDivisión de Neurociencias Básicas, Instituto Nacional de Rehabilitación-LGII, México City 14389, Mexico.ORCID 0000-0002-9410-8535

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Parkinson's disease (PD) is characterized by progressive degeneration of nigrostriatal dopaminergic neurons, leading to motor dysfunction and compensatory postsynaptic dopamine receptor alterations. Valproic acid (VPA), a histone deacetylase inhibitor, has shown neuroprotective properties; however, its dose-dependent effects on dopaminergic integrity and dopamine D2 receptor (D2R) regulation remain unclear. Adult male Wistar rats received VPA (200 or 400 mg/kg, p.o.) or vehicle for 20 days prior to unilateral 6-hydroxydopamine (6-OHDA) lesioning. Motor performance was evaluated using the beam balance test, exploratory behavior in the open field, striatal dopamine levels by PLC-electrochemical detection, and D2R protein expression by Western blot. The 6-OHDA lesion induced marked motor deficits, reduced striatal dopamine content, and significantly increased D2R expression. VPA at 200 mg/kg produced only minor, non-significant effects. In contrast, VPA at 400 mg/kg preserved motor performance, attenuated dopamine depletion, and normalized striatal D2R expression. These findings demonstrate a clear dose-dependent neuroprotective effect of VPA and indicate that stabilization of postsynaptic D2R expression accompanies preservation of dopaminergic terminals in the 6-OHDA rat model.

Indexed as

Corpus StriatumMotor ActivityNeuroprotective AgentsParkinson DiseaseReceptors, Dopamine D2Valproic AcidAnimalsDisease Models, AnimalDopamineDose-Response Relationship, DrugMaleOxidopamineRatsRats, WistarDopamineNeuroprotective AgentsOxidopamineReceptors, Dopamine D2Valproic Acid6-OHDAdopamine D2 receptorHDAC inhibitorHPLCneuroprotectionParkinson’s diseasevalproic acid

Identifiers

PMID41828543
PMCPMC12985796

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.